🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Sun-Gou Ji, Ph.D., VP and Head of Computational Genetics, will be speaking at the Festival of Genomics Boston! He’ll explore how real-world genomic data can uncover the true prevalence of rare diseases and why that is important when thinking about putting patients first. Catch

Our medical affairs team recently attended the Annual Meeting of the American Association of Heart Failure Nurses (American Association of Heart Failure Nurses), where we had the privilege of connecting with dedicated heart failure professionals and engaging in meaningful scientific discussions. We're grateful for

❤️➡️bit.ly/44oSGo2 New publication in Journal of Cardiovascular Pharmacology highlighting more data for acoramidis as a near-complete TTR stabilizer.

Learn more and register ➡️bit.ly/4l2Zn6d Join us for an investor webinar on Friday, July 11 at 8:00 AM ET with Matthew Wicklund, M.D., FAAN of UT Health San Antonio, where he will share an overview on limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9).

Incredible to connect with families & clinicians, hear from LGMD advocates, and see real momentum in research & trial updates at this year’s Iowa Wellstone Dystroglycanopathy Patient & Family Conference. We are grateful to stand alongside this community, and we appreciate being a

Today, we announced the closure of a European royalty financing for our near-complete stabilizer in transthyretin amyloid cardiomyopathy of $300 million with HealthCare Royalty and Blue Owl Capital. Learn more: bit.ly/4lwl8Lm

💚👉curelgmd2i.com/videos/ We’re inspired by the powerful patient and caregiver voices elevated by CureLGMD2i. One example of this is Jennifer and Ryan’s story, which shows the true resilience of how families navigate a rare disease diagnosis like LGMD2I/R9.

Register 📆➡️ bit.ly/3TPuDtf Don’t miss our LGMD2I/R9 investor webinar on Friday, July 11 at 8:00 AM ET with Matthew Wicklund, M.D., FAAN of UT Health San Antonio.

Heading to PHARMACHON in SF on July 12? Join us alongside The Chandler Project 🦋 to learn about the latest in research developments. bit.ly/3I0McUI

We’re excited to join Endocrine Society at #ENDO2025 to share updates from our ADH1 program, including 42-month Phase 2b results from encaleret treatment, pediatric baseline characteristics from CLARIFY, our disease monitoring study, insights from our genetic testing program, &

Reminder to register 📆➡️ bit.ly/3TPuDtf Join us for our investor webcast featuring Matthew Wicklund, M.D., FAAN of UT Health San Antonio & LGMD2I/R9 exec team who will discuss LGMD2I/R9 and review BBP-418 progress.

Diagnosed with tuberous sclerosis complex (#TSC) at age 6, Daniel shares his experiences overcoming stigma and isolation, to becoming an advocacy leader on our latest #OnRarePodcast. TSC is a rare genetic condition that causes growth of non-malignant  tumors throughout the body.

Motor development in children with achondroplasia often happens on a different timeline. Milestones like crawling or walking may take longer to appear and develop in unique ways. What matters most is supporting each child's progress at the pace that's right for them.

We’re thrilled to share that we received the 2025 Rare Impact Award from @rarediseases! Learn more: prnewswire.com/news-releases/…

Check out the podcast ➡️:bit.ly/4lX2xbQ Listening to the #raredisease community is at the heart of the On Rare podcast which explores the lived experiences of people navigating rare disease through their own voices. Hosted by BridgeBio's head of patient advocacy and

💚➡️ We’re headed to the Speak Foundation’s International LGMD Conference! Join us for our presentation on FORTIFY, our Phase 3 study for LGMD2I/R9 and a round table discussion focused on LGMD2I/R9 care and potential new therapies.

What causes tuberous sclerosis complex #TSC ? In the latest #OnRarePodcast episode, Che-Wei Chang, Ph.D., Principal Scientist, GondolaBio, part of the BridgeBio ecosystem, shares how TSC causes non-cancerous tumors, often impacting the brain, kidneys, skin, and other organs.

An unforgettable moment – our team accepted the 2025 #RareImpact Award from @rarediseases. A heartfelt thank-you to #NORD for recognizing the work we do for people living with rare and genetic diseases and for being a dependable partner to the community.

BridgeBio is hosting its Q2 2025 earnings call on Tuesday, August 5 at 4:30 pm ET. Tune in for updates on our programs and progress: bit.ly/46n58Hj

Our new study in American Journal of Human Genetics confirms that ADH1 is more prevalent & underdiagnosed than previously thought. Learn more about the findings: bit.ly/4macQJE